Left Atrial Appendage Occlusion and Rhythm Restoration in AF Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the safety and feasibility of performing pulsed-field ablation of the atria with the Volt PFA System together with implantation of the Amulet 2 left atrial appendage occluder in patients who are indicated for both AF ablation and LAA occlusion. The study targets adults with non-valvular AF, including paroxysmal and persistent forms, who meet specific risk criteria and can discontinue anticoagulation after an initial period. Primary focuses are procedural safety, acute feasibility, and short-term outcomes related to rhythm control and LAA closure. Participants will undergo catheter ablation (PVI) followed by LAA occluder implantation, with post-procedure pharmacologic management per protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject must provide written informed consent prior to any clinical investigation-related procedure.
* 18 years of age or older, or the age of legal consent
* CHA2DS2-VASc score of ≥ 3 for women and ≥ 2 for men
* Able to stop anticoagulation by 90 days post index procedure
* Able to adhere to the protocol defined post-concomitant procedure pharmacologic regimen of OAC for at least 60 days followed by SAPT
* Plans to undergo a catheter ablation procedure including PVI due to symptomatic, recurrent, drug-refractory PAF or PersAF
* Documented symptomatic PAF or PersAF. Documentation requirements are as follows:

Paroxysmal:

* Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes of PAF within the 12 months prior to enrollment AND
* One electrocardiographically documented PAF episode within 12 months prior to enrollment.

Persistent: Continuous AF sustained beyond 7 days and less than 1 year that is documented by

* Physician's note, AND either
* 24-hour Holter within 180 days prior to enrollment, showing continuous AF, OR
* Two electrocardiograms (from any form of rhythm monitoring) showing continuous AF:

  * That are taken at least 7 days apart but less than 12 months apart
  * If electrograms are more than 12 months apart, there must be one or more Sinus Rhythm recordings in between or within 12 months prior to consent/enrollment
  * The most recent electrocardiogram must be within 180 days of enrollment.

NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of continuous AF from another ECG device.

Exclusion Criteria:

* Known contraindication or allergy to NOACs or aspirin, preventing use of the drugs post-procedure
* Required to take P2Y12 platelet inhibitor after the study procedure (e.g., due to percutaneous coronary intervention)
* Patients with heart prosthetic valves
* Patient implanted with an inferior vena cava filter
* Patients with left ventricular ejection fraction ≤30%
* Patients with NYHA Class IV heart failure
* Patients who have undergone any invasive intervention or surgery within 30 days prior to the index procedure (diagnostic catheterization is not within scope, however, percutaneous coronary intervention is within scope)
* Patients who have experienced stroke or transient ischemic attack within 90 days prior to study procedure
* Patients who have had previous attempt at LAA surgical or epicardial intervention (e.g., stapling, suturing, ligation, epicardial LAA management device)
* Patients previously diagnosed long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)
* Patients with arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures within 90 days prior to the study procedure
* Patients unable to receive heparin or an acceptable alternative to achieve adequate intra-procedural anticoagulation
* Patients with a stent, constriction, or stenosis in a pulmonary vein
* Patients with severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2)
* Patients with severe renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or on chronic dialysis
* Patients with severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
* Patients with hypertrophic cardiomyopathy (maximal LV wall thickness ≥ 15 mm in the absence of abnormal loading conditions such as hypertension or aortic stenosis)

Where it's running

• UZ Brussel
  Brussels, B Cap R, Belgium Recruiting
• Motol and Homolka University Hospital
  Prague, Czech Republic, Czechia Recruiting
• Rigshospitalet
  Copenhagen, Copenha, Denmark Recruiting
• Cardioangiologisches Centrum am Bethanien Krankenhaus
  Frankfurt am Main, Hesse, Germany Recruiting
• Universitätsklinikum Schleswig-Holstein - Campus Lübeck
  Lübeck, Schlesw, Germany Recruiting
• Deutsches Herzzentrum der Charite
  Berlin, State of Berlin, Germany Recruiting

Study contacts

• Study coordinator: Abeer Madbouly, Ph. D
• Email: abeer.madbouly@abbott.com
• Phone: 651-497-5099

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Budiodarone for paroxysmal AF: a dose-escalation safety and feasibility study

  This study tests whether budiodarone is safe and helps control paroxysmal atrial fibrillation in about 100 adults over 6 months, using dose adjustments guided by AF monitoring.

  Recruiting at 4 sites Phase 2 Xyra, LLC · Gdynia and 3 other locations · NCT07792239

• Progressive Resistance Training First to Help AF and HFpEF Patients Feel Better

  This trial tests whether starting with progressive resistance training before aerobic exercise can improve exercise capacity and quality of life in people aged 60 and older who have atrial fibrillation and HFpEF.

  Recruiting Northwestern University · Chicago, Illinois · NCT07324772

• Redo AF ablation using the Sphere-9 catheter and Affera system for recurrent paroxysmal and persistent atrial fibrillation

  The study will try the Sphere-9 catheter with the Affera ablation and mapping systems for adults who have symptomatic recurrent paroxysmal or persistent atrial fibrillation after one prior ablation.

  Recruiting at 24 sites Medtronic Cardiac Ablation Solutions · Birmingham, Alabama and 29 other locations · NCT07298473

• Coherent Sine-Burst Electroporation (CSE) Ablation for Atrial Fibrillation

  This study will test whether the Argá Medtech CSE electroporation device can safely and effectively ablate heart tissue to treat adults with symptomatic paroxysmal or persistent atrial fibrillation who have not responded to drugs.

  Recruiting at 27 sites Arga Medtech SA · Birmingham, Alabama and 26 other locations · NCT06784466

• Pulsed field versus radiofrequency approaches to change vagal nerve effects during pulmonary vein isolation for paroxysmal AF

  This study tests whether pulsed field ablation, alone or combined with radiofrequency, changes vagal nerve activity during pulmonary vein isolation in people with paroxysmal atrial fibrillation.

  Recruiting VZW Cardiovascular Research Center Aalst · Aalst, Belgium · NCT06647485

• Evaluating a new catheter for treating persistent atrial fibrillation

  This study is testing a new catheter to see if it can safely help people with persistent atrial fibrillation who haven't found relief from other treatments.

  Recruiting at 4 sites Boston Scientific Corporation · Brussels and 3 other locations · NCT06510556

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.